$GEVA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SYNAGEVA BIOPHARMA CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SYNAGEVA BIOPHARMA CORP. Get notifications about new insider transactions in SYNAGEVA BIOPHARMA CORP for free.
Page: < prev 1 ... 4 5 6 7 8 9 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 2006 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Sell | J | 0.00 | 84,102 | 0 | 0 | 84.1 K to 0 (-100.00 %) |
| Apr 28 2006 | GEVA | SYNAGEVA BIOPHARMA ... | Baker Brothers Life Sciences C ... | Director | Sell | J | 0.00 | 1,144,755 | 0 | 0 | 1.1 M to 0 (-100.00 %) |
| Apr 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | Skolsky Steven D | Chief Executive Off ... | Option Exercise | A | 12.80 | 16,618 | 212,710 | 16,618 | |
| Apr 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 12.80 | 9,054 | 115,891 | 9,054 | |
| Apr 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 12.80 | 9,054 | 115,891 | 9,054 | |
| Apr 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Director of Finance | Option Exercise | A | 12.80 | 1,696 | 21,709 | 1,696 | |
| Mar 21 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 7,153 | 2,432 | 0 | |
| Mar 21 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | D | 13.53 | 7,153 | 96,780 | 9,000 | 16.2 K to 9 K (-44.28 %) |
| Mar 21 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 7,153 | 2,432 | 16,153 | 9 K to 16.2 K (+79.48 %) |
| Mar 21 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 30 | 600 | 30 | |
| Feb 22 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 2,009 | 683 | 0 | |
| Feb 22 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 12.00 | 2,009 | 24,108 | 47,716 | 49.7 K to 47.7 K (-4.04 %) |
| Feb 22 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 2,009 | 683 | 49,725 | 47.7 K to 49.7 K (+4.21 %) |
| Jan 25 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 2,009 | |
| Jan 25 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 11.30 | 3,060 | 34,578 | 47,716 | 50.8 K to 47.7 K (-6.03 %) |
| Jan 25 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,776 | 47.7 K to 50.8 K (+6.41 %) |
| Jan 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Director of Finance | Option Exercise | A | 11.79 | 1,696 | 19,996 | 1,696 | |
| Jan 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 11.79 | 9,054 | 106,747 | 9,054 | |
| Jan 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 11.79 | 9,054 | 106,747 | 9,054 | |
| Jan 03 2006 | GEVA | SYNAGEVA BIOPHARMA ... | Skolsky Steven D | Chief Executive Off ... | Option Exercise | A | 11.79 | 16,618 | 195,926 | 16,618 | |
| Dec 22 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 5,069 | |
| Dec 22 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 12.10 | 3,060 | 37,026 | 47,716 | 50.8 K to 47.7 K (-6.03 %) |
| Dec 22 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,776 | 47.7 K to 50.8 K (+6.41 %) |
| Dec 09 2005 | GEVA | SYNAGEVA BIOPHARMA ... | CROUT J RICHARD | Director | Buy | P | 12.00 | 300 | 3,599 | 4,300 | 4 K to 4.3 K (+7.50 %) |
| Nov 21 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 8,129 | |
| Nov 21 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 13.25 | 3,060 | 40,545 | 47,472 | 50.5 K to 47.5 K (-6.06 %) |
| Nov 21 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,532 | 47.5 K to 50.5 K (+6.45 %) |
| Oct 24 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 11,189 | |
| Oct 24 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 14.00 | 3,060 | 42,840 | 47,472 | 50.5 K to 47.5 K (-6.06 %) |
| Oct 24 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,532 | 47.5 K to 50.5 K (+6.45 %) |
| Oct 03 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 15.65 | 9,054 | 141,695 | 9,054 | |
| Oct 03 2005 | GEVA | SYNAGEVA BIOPHARMA ... | Skolsky Steven D | Chief Executive Off ... | Option Exercise | A | 15.65 | 16,618 | 260,072 | 16,618 | |
| Oct 03 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 15.65 | 9,054 | 141,695 | 9,054 | |
| Oct 03 2005 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Director of Finance | Option Exercise | A | 15.65 | 1,696 | 26,542 | 1,696 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 10 | 200 | 10 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 5 | 100 | 5 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 10 | 200 | 10 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 10 | 200 | 10 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 10 | 200 | 10 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 10 | 200 | 10 | |
| Sep 16 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | S | 20.00 | 10 | 200 | 10 | |
| Sep 15 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 14,249 | |
| Sep 15 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 13.56 | 3,060 | 41,494 | 47,472 | 50.5 K to 47.5 K (-6.06 %) |
| Sep 15 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,532 | 47.5 K to 50.5 K (+6.45 %) |
| Aug 29 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 17,309 | |
| Aug 29 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 11.30 | 3,060 | 34,578 | 47,472 | 50.5 K to 47.5 K (-6.06 %) |
| Aug 29 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,532 | 47.5 K to 50.5 K (+6.45 %) |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 12.62 | 75,000 | 946,500 | 75,000 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 12.62 | 9,054 | 114,261 | 9,054 | |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 11.35 | 6,300 | 71,505 | 6,300 | 0 to 6.3 K |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 11.35 | 4,100 | 46,535 | 4,100 | 0 to 4.1 K |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 11.35 | 11,000 | 124,850 | 11,000 | 0 to 11 K |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 11.35 | 8,300 | 94,205 | 8,300 | 0 to 8.3 K |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 12.02 | 78,100 | 938,762 | 330,900 | 252.8 K to 330.9 K (+30.89 %) |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 11.94 | 75,000 | 895,500 | 252,800 | 177.8 K to 252.8 K (+42.18 %) |
| Sep 12 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 11.41 | 14,800 | 168,868 | 177,800 | 163 K to 177.8 K (+9.08 %) |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 12.62 | 11,250 | 141,975 | 11,250 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 12.62 | 11,250 | 141,975 | 11,250 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | COOK GARY | Director | Option Exercise | A | 12.62 | 13,750 | 173,525 | 13,750 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | Graham Andrew L | Director of Finance | Option Exercise | A | 12.62 | 1,696 | 21,404 | 1,696 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 12.62 | 9,054 | 114,261 | 9,054 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | SANDERS CHARLES A | Director | Option Exercise | A | 12.62 | 12,500 | 157,750 | 12,500 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Option Exercise | A | 12.62 | 20,000 | 252,400 | 20,000 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | CROUT J RICHARD | Director | Option Exercise | A | 12.62 | 12,500 | 157,750 | 12,500 | |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Option Exercise | A | 12.62 | 12,500 | 157,750 | 12,500 | |
| Jul 15 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 20,369 | |
| Jul 15 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 11.25 | 3,060 | 34,425 | 47,472 | 50.5 K to 47.5 K (-6.06 %) |
| Jul 15 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,532 | 47.5 K to 50.5 K (+6.45 %) |
| Aug 11 2005 | GEVA | SYNAGEVA BIOPHARMA ... | Skolsky Steven D | Chief Executive Off ... | Option Exercise | A | 12.62 | 16,618 | 209,719 | 16,618 | |
| Jun 28 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | M | 0.34 | 3,060 | 1,040 | 23,429 | |
| Jun 28 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 9.66 | 1,442 | 13,930 | 47,472 | 48.9 K to 47.5 K (-2.95 %) |
| Jun 28 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 9.67 | 1,358 | 13,132 | 48,914 | 50.3 K to 48.9 K (-2.70 %) |
| Jun 28 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Sell | S | 9.75 | 260 | 2,535 | 50,272 | 50.5 K to 50.3 K (-0.51 %) |
| Jun 28 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Buy | M | 0.34 | 3,060 | 1,040 | 50,532 | 47.5 K to 50.5 K (+6.45 %) |
| May 02 2005 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 9.90 | 10,000 | 99,000 | 173,982 | 164 K to 174 K (+6.10 %) |
| Apr 01 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 11.15 | 23,500 | 262,025 | 23,500 | |
| Apr 01 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 11.15 | 11,800 | 131,570 | 11,800 | |
| Jan 04 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 14.26 | 23,500 | 335,110 | 23,500 | |
| Jan 04 2005 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 14.26 | 11,800 | 168,268 | 11,800 | |
| Jan 04 2005 | GEVA | SYNAGEVA BIOPHARMA ... | Koszalka George W | Option Exercise | A | 14.26 | 8,200 | 116,932 | 8,200 | ||
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL II GP LL ... | Director | Sell | J | 0.00 | 586,556 | 0 | 1,144,755 | 1.7 M to 1.1 M (-33.88 %) |
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Gift | G | 0.00 | 825 | 0 | 825 | 1.7 K to 825 (-50.00 %) |
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Gift | G | 0.00 | 825 | 0 | 825 | 1.7 K to 825 (-50.00 %) |
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Gift | G | 0.00 | 825 | 0 | 825 | 1.7 K to 825 (-50.00 %) |
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Gift | G | 0.00 | 825 | 0 | 825 | 1.7 K to 825 (-50.00 %) |
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.67 | 1,650 | 19,256 | 167,282 | 165.6 K to 167.3 K (+1.00 %) |
| Nov 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.66 | 1,650 | 19,239 | 165,632 | 164 K to 165.6 K (+1.01 %) |
| Oct 04 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BOLOGNESI DANI P | Chief Scientific Of ... | Option Exercise | A | 15.95 | 23,500 | 374,825 | 23,500 | |
| Oct 04 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 15.95 | 11,800 | 188,210 | 11,800 | |
| Oct 04 2004 | GEVA | SYNAGEVA BIOPHARMA ... | Koszalka George W | Option Exercise | A | 15.95 | 8,200 | 130,790 | 8,200 | ||
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL GP LLC | Director | Buy | P | 13.32 | 20,850 | 277,722 | 1,253,084 | 1.2 M to 1.3 M (+1.69 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL GP LLC | Director | Buy | P | 13.56 | 16,680 | 226,166 | 1,232,234 | 1.2 M to 1.2 M (+1.37 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL GP LLC | Director | Buy | P | 12.99 | 1,355 | 17,603 | 1,215,554 | 1.2 M to 1.2 M (+0.11 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL GP LLC | Director | Buy | P | 12.55 | 31,275 | 392,617 | 1,214,199 | 1.2 M to 1.2 M (+2.64 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BROS CAPITAL GP LLC | Director | Buy | P | 13.32 | 4,202 | 55,971 | 331,139 | 326.9 K to 331.1 K (+1.29 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BROS CAPITAL GP LLC | Director | Buy | P | 13.56 | 3,361 | 45,572 | 326,937 | 323.6 K to 326.9 K (+1.04 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BROS CAPITAL GP LLC | Director | Buy | P | 12.99 | 273 | 3,547 | 323,576 | 323.3 K to 323.6 K (+0.08 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BROS CAPITAL GP LLC | Director | Buy | P | 12.55 | 6,303 | 79,126 | 323,303 | 317 K to 323.3 K (+1.99 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER TISCH CAPITAL GP LLC | Director | Buy | P | 13.32 | 2,626 | 34,978 | 286,835 | 284.2 K to 286.8 K (+0.92 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER TISCH CAPITAL GP LLC | Director | Buy | P | 13.56 | 2,100 | 28,474 | 284,209 | 282.1 K to 284.2 K (+0.74 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER TISCH CAPITAL GP LLC | Director | Buy | P | 12.99 | 171 | 2,221 | 282,109 | 281.9 K to 282.1 K (+0.06 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER TISCH CAPITAL GP LLC | Director | Buy | P | 12.55 | 3,938 | 49,436 | 281,938 | 278 K to 281.9 K (+1.42 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL II GP LL ... | Director | Buy | P | 13.32 | 22,322 | 297,329 | 1,731,311 | 1.7 M to 1.7 M (+1.31 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL II GP LL ... | Director | Buy | P | 13.56 | 17,859 | 242,152 | 1,708,989 | 1.7 M to 1.7 M (+1.06 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL II GP LL ... | Director | Buy | P | 12.99 | 1,450 | 18,837 | 1,691,130 | 1.7 M to 1.7 M (+0.09 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER BIOTECH CAPITAL II GP LL ... | Director | Buy | P | 12.55 | 33,484 | 420,348 | 1,689,680 | 1.7 M to 1.7 M (+2.02 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.08 | 7,000 | 91,560 | 163,000 | 156 K to 163 K (+4.49 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.04 | 10,000 | 130,400 | 156,000 | 146 K to 156 K (+6.85 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.05 | 8,000 | 104,400 | 146,000 | 138 K to 146 K (+5.80 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.08 | 8,000 | 104,640 | 138,000 | 130 K to 138 K (+6.15 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 12.39 | 6,500 | 80,535 | 130,000 | 123.5 K to 130 K (+5.26 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 12.52 | 2,000 | 25,040 | 123,500 | 121.5 K to 123.5 K (+1.65 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 12.72 | 2,500 | 31,800 | 121,500 | 119 K to 121.5 K (+2.10 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.00 | 2,800 | 36,400 | 119,000 | 116.2 K to 119 K (+2.41 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.01 | 6,000 | 78,060 | 116,200 | 110.2 K to 116.2 K (+5.44 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.03 | 1,800 | 23,454 | 110,200 | 108.4 K to 110.2 K (+1.66 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.12 | 2,400 | 31,488 | 108,400 | 106 K to 108.4 K (+2.26 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.16 | 4,000 | 52,640 | 106,000 | 102 K to 106 K (+3.92 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.15 | 10,000 | 131,500 | 102,000 | 92 K to 102 K (+10.87 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.09 | 7,200 | 94,248 | 92,000 | 84.8 K to 92 K (+8.49 %) |
| Sep 14 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Buy | P | 13.14 | 4,800 | 63,072 | 84,800 | 80 K to 84.8 K (+6.00 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.10 | 3,098 | 34,388 | 163,982 | 160.9 K to 164 K (+1.93 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.08 | 200 | 2,216 | 160,884 | 160.7 K to 160.9 K (+0.12 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.07 | 400 | 4,428 | 160,684 | 160.3 K to 160.7 K (+0.25 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.06 | 100 | 1,106 | 160,284 | 160.2 K to 160.3 K (+0.06 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.05 | 300 | 3,315 | 160,184 | 159.9 K to 160.2 K (+0.19 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.04 | 800 | 8,832 | 159,884 | 159.1 K to 159.9 K (+0.50 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.03 | 100 | 1,103 | 159,084 | 159 K to 159.1 K (+0.06 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.00 | 4,202 | 46,222 | 158,984 | 154.8 K to 159 K (+2.71 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 10.99 | 1,300 | 14,287 | 154,782 | 153.5 K to 154.8 K (+0.85 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 10.96 | 100 | 1,096 | 153,482 | 153.4 K to 153.5 K (+0.07 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 10.95 | 1,100 | 12,045 | 153,382 | 152.3 K to 153.4 K (+0.72 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 10.94 | 100 | 1,094 | 152,282 | 152.2 K to 152.3 K (+0.07 %) |
| Aug 05 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 10.92 | 200 | 2,184 | 152,182 | 152 K to 152.2 K (+0.13 %) |
| Sep 09 2004 | GEVA | SYNAGEVA BIOPHARMA ... | Skolsky Steven D | Chief Executive Off ... | Option Exercise | A | 11.51 | 350,000 | 4,028,500 | 350,000 | |
| Sep 09 2004 | GEVA | SYNAGEVA BIOPHARMA ... | Skolsky Steven D | Chief Executive Off ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
| Aug 02 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Buy | P | 11.18 | 8,000 | 89,440 | 151,982 | 144 K to 152 K (+5.56 %) |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 14.14 | 11,250 | 159,075 | 11,250 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Option Exercise | A | 14.14 | 10,000 | 141,400 | 10,000 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | COOK GARY | Director | Option Exercise | A | 14.14 | 12,500 | 176,750 | 12,500 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | Koszalka George W | Option Exercise | A | 14.14 | 8,200 | 115,948 | 8,200 | ||
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | Koszalka George W | Grant | A | 0.00 | 11,000 | 0 | 13,549 | 2.5 K to 13.5 K (+431.54 %) | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | CROUT J RICHARD | Director | Option Exercise | A | 14.14 | 12,500 | 176,750 | 12,500 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | LIPTON JEFFREY M | Director | Option Exercise | A | 14.14 | 17,500 | 247,450 | 17,500 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | TANG KEVIN C | Director | Option Exercise | A | 14.14 | 11,250 | 159,075 | 11,250 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | SANDERS CHARLES A | Director | Option Exercise | A | 14.14 | 12,500 | 176,750 | 12,500 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | CREECH TIMOTHY J | Vice President of F ... | Option Exercise | A | 14.14 | 5,200 | 73,528 | 5,200 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | CREECH TIMOTHY J | Vice President of F ... | Grant | A | 0.00 | 7,000 | 0 | 19,462 | 12.5 K to 19.5 K (+56.17 %) |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Option Exercise | A | 14.14 | 11,800 | 166,852 | 11,800 | |
| Jun 24 2004 | GEVA | SYNAGEVA BIOPHARMA ... | BONCZEK ROBERT R | CFO and General Cou ... | Grant | A | 0.00 | 15,700 | 0 | 41,054 | 25.4 K to 41.1 K (+61.92 %) |